New digital tool aims to curb antibiotic overuse for lung infections
NCT ID NCT06331364
First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 2 times
Summary
This study tests an electronic decision support tool to help doctors diagnose and treat lower respiratory tract infections. About 765 patients in Sri Lankan hospitals will use the tool, and researchers will compare their outcomes and antibiotic use to those receiving usual care. The goal is to see if the tool improves diagnosis and reduces unnecessary antibiotics.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- electronic clinical decision support tool (eCDST)
- What this could lead to
- If successful, this tool could help doctors diagnose lower respiratory infections more accurately and reduce unnecessary antibiotic use.
- What could go wrong
- This is a relatively small trial in three hospitals, so results may not apply to other settings. The tool may not improve outcomes or could be difficult to implement.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 765 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Feb 2026
- Expected to finish
-
Jul 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
14 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Admitted within prior 48 hours 2. Have evidence of new acute respiratory illness (\<14 days of symptoms), as indicated by at least one of the following: 1. New cough or sputum production 2. Chest pain 3. Dyspnea or tachypnea (respiratory rate \>20 breaths/minute) 4. Abnormal lung examination 3. Have evidence of acute infection, as indicated by at least one of the following: 1. Self-reported fever or chills 2. Documented fever ≥38 ̊ C (100.4 ̊ F) 3. Documented hypothermia \<35.5 ̊ C (95.9 ̊ F) 4. Leukocytosis (white blood cell count \>10,000/mm3) 5. Leukopenia (white blood cell count \<3000/mm3) 6. New altered mental status 4. Ability and willingness of patient, parent or legally authorized representative (LAR) to give informed consent 5. Ability of children 14-17 years of age to provide assent 6. Ability to complete follow-up encounter at 30 days in person or by telephone Exclusion Criteria: 1. Hospitalized recently (within last 28 days) 2. If they have been enrolled into this clinical trial previously 3. Surgery in the past 7 days 4. If they are unable or unwilling to complete the follow-up encounter 5. If they will likely be transferred from the medical wards within 24 hours of enrollment (to another ward or to another hospital) 6. If they have underlying conditions or circumstances for which physicians would be unlikely to withhold antibacterials: 1. Vasopressor therapy 2. Cystic fibrosis 3. Known severe immunosuppression (i. Cancer or another condition with neutropenia (absolute neutrophil count \<1000/ microL; ii. Solid- organ or hematopoietic stem-cell transplant within the previous 90 days; iii. Active graft-versus-host disease or bronchiolitis obliterans; iv. On chronic steroids equivalent to prednisone 20mg daily for ≥ 2 weeks or other targeted cytotoxic or biologic immunosuppressants within the prior 4 weeks; v. Human immunodeficiency virus infection with a CD4 cell count \<200/mm3) 4. Have an accompanying non-respiratory infection 5. Have evidence of a lung abscess or empyema 6. Have respiratory failure at enrollment, evidenced by use of non-invasive or invasive ventilation
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Lower resp tract infection are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
3 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Base Hospital Balapitiya
RECRUITINGBalapitiya, Sri Lanka
-
District General Hospital Matara
RECRUITINGMatara, Sri Lanka
-
Galle National Hospital
RECRUITINGKarapitiya, Sri Lanka
More trials for these conditions
Other studies related to the condition(s) this trial covers.